ArticleNPJ precision oncology2026
Development and validation of artificial intelligence-based model for bladder cancer immunophenotyping using whole slide images.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The classification of immunophenotypes in muscle-invasive bladder cancer (MIBC) is critical for predicting immunotherapy response and clinical outcomes, yet current assessment methods lack standardization and scalability. We developed and validated an artificial intelligence-based MIBC Immunophenotype Diagnostic System using computational pathology to enable reproducible classification from routine hematoxylin and eosin-stained whole-slide images. In this multicenter retrospective diagnostic study, consecutive patients who underwent partial or radical cystectomy between 2014 and 2024 from two Chinese hospitals and The Cancer Genome Atlas cohort were included, with an independent cohort receiving immune checkpoint inhibitors for treatment efficacy evaluation. The system integrates Hover-Net-based nuclear classification with cell structure graph networks to model spatial cellular interactions within the tumor microenvironment. Across external validation cohorts, the model achieved macro-area under the curve values of 0.922-0.956 and macro-accuracy of 0.922-0.950, demonstrating robust generalizability. In a human-AI collaboration study, the system outperformed junior and senior pathologists and significantly improved junior pathologists' diagnostic accuracy while reducing review time. Predicted Inflamed tumors exhibited enriched CD8+ T-cell infiltration, elevated checkpoint gene expression, and stronger correlation with immunotherapy response. These findings support clinical translation for precision immuno-oncology in bladder cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.